Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 58

Results For "IDA"

1816 News Found

Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
News | December 24, 2024

Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger

The transaction is expected to result in approximately $175 million to support further development of IMG-007


Shilpa Medicare’s Unit VII, Nacharam, Hyderabad receives GMP certificate from EMA, Austria
News | December 22, 2024

Shilpa Medicare’s Unit VII, Nacharam, Hyderabad receives GMP certificate from EMA, Austria

The company has received the GMP Certification after successful closure of the inspection


Merck to discontinue KeyVibe and Keyform clinical trials
Diagnostic Center | December 17, 2024

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program


Merck to acquire HUB Organoids to advance cell culture portfolio
News | December 17, 2024

Merck to acquire HUB Organoids to advance cell culture portfolio

Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development


Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'
Healthcare | December 16, 2024

Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'

A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%


Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody
Diagnostic Center | December 10, 2024

Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody

Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma


Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease
Biotech | December 07, 2024

Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease

GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization


FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy
Drug Approval | December 07, 2024

FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy

Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients